Previous close | 1.6430 |
Open | 1.6490 |
Bid | 1.5305 x 0 |
Ask | 1.7720 x 0 |
Day's range | 1.6490 - 1.6545 |
52-week range | 1.1995 - 5.6000 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 27 Feb 2023 - 03 Mar 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Chimerix (CMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NEW YORK, November 10, 2022--Rubric Capital Management LP ("Rubric"), an investment adviser whose managed funds and accounts collectively own approximately 8.5% of the common stock of Chimerix, Inc. ("Chimerix" or the "Company") (NASDAQ: CMRX), today sent a letter to Chimerix’s Board of Directors (the "Board").
Chimerix, Vista Oil & Gas and Arcus Biosciences have been highlighted in this Screen of The Week article.